Search Results 161-170 of 911 for HTX BacklinkAZ

  1. Hereditary hemorrhagic telangiectasia - Doctors and departments - Mayo Clinic

    This inherited blood vessel condition can cause bad nosebleeds, strokes, bleeding in the digestive tract and anemia.

  2. Drugs and Supplements that Start with D - Mayo Clinic

    Explore a comprehensive list of prescription and over-the-counter medications starting with the letter “D” to learn about drug side effects, proper use and ...

  3. Hereditary hemorrhagic telangiectasia - Doctors and departments - Mayo Clinic

    This inherited blood vessel condition can cause bad nosebleeds, strokes, bleeding in the digestive tract and anemia.

  4. Efficacy and Safety of Treatment With Alpelisib Plus Endocrine Therapy in Patients With HR+, HER2-negative aBC, With PIK3CA Mutations, Whose Disease Has Progressed on or After CDK 4/6 Treatment With an Aromatase Inhibitor (AI) or Fulvestrant - Mayo Clinic

    Efficacy and Safety of Treatment With Alpelisib Plus Endocrine Therapy in Patients With HR+, HER2-negative aBC, With PIK3CA Mutations, Whose Disease Has ...

  5. Clinical trials - Oncology (Medical)

    The purpose of this study is to develop a pan-gynecologic cancer detection test using gynecologic (unique endometrial, cervical, and ovarian cancer) ...

  6. Biotinylated Vectors as Ligand Screening Platforms - Virology, Vector and Vaccine Engineering: Michael A. Barry - Mayo Clinic Research

    Learn about biotinylated vectors as ligand screening platforms in the Virology, Vector and Vaccine Engineering Laboratory of Michael A. Barry, Ph.D., ...

  7. Denileukin diftitox-cxdl (intravenous route) - Side effects & uses - Mayo Clinic

    Denileukin diftitox-cxdl injection is used to treat a type of skin cancer called Stage I to III cutaneous T-cell lymphoma (CTCL) that has come back (relapsed) ...

  8. Hereditary hemorrhagic telangiectasia - Doctors and departments - Mayo Clinic

    This inherited blood vessel condition can cause bad nosebleeds, strokes, bleeding in the digestive tract and anemia.

  9. Evaluate the Effect of ALLN-177 in Reducing Urinary Oxalate in Patients With Secondary Hyperoxaluria and Kidney Stones Over 28 Days - Mayo Clinic

    About this study. Evaluate the safety, tolerability, and efficacy of 28 days of treatment with ALLN-177 for reducing urinary oxalate excretion in patients ...

  10. Trifecta™ GT Post Market Clinical Follow-up

    The objective of this study is to evaluate the safety and performance of the Trifecta™ GT (Glide Technology) valve through 5 year follow-up in a prospective, ...